CD19 and neoplasm: A well-defined population of cells co-expressing CD19+ and CD20+ could be detected in 28 out of 38 tumor samples with a non-significant increase in metastatic disease (8.3% in stage IV vs. 6.4% in stage I–III, p=0.28).